Tuberous sclerosis complex

5 trials 1 recruiting MedDRA PT
5 Registered trials
1 Recruiting
5 Unique sponsors
4 Unique IMPs
5 Commercial trials
Drug classes (ATC)
N Neurology/Psychiatry (ATC N) 2
— ATC code not specified 3
Mechanism of action (INN-stem analysis)
Unknown / small molecule 4 substances
Phase III: 2 Phase II: 1 Phase I/II: 1 Phase III/IV: 1

Filter these 5 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 5 trials

Phase III

2 trials
  • Gw Research Limited Commercial
    CANNABIDIOL
    2023-505851-33-00 2 countries 2024 n=10 Orphan
    Ended
  • Oils4cure S.L. Commercial
    DRONABINOL, CANNABIDIOL
    2024-520171-27-00 1 country 2023 n=84
    Recruiting

Phase II

1 trial
  • Noema Pharma AG Commercial
    BASIMGLURANT
    2024-512611-53-00 3 countries 2023 n=31
    Ended

Phase I/II

1 trial
  • Grin Therapeutics Inc. Commercial
    RADIPRODIL
    2023-506301-20-00 5 countries 2024 n=28
    Ended

Phase III/IV

1 trial
  • Jazz Pharmaceuticals Research UK Limited Commercial
    CANNABIDIOL
    2023-507426-17-00 1 country 2024 n=20 Orphan
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Jazz Pharmaceuticals Research UK Limited Commercial 1 Phase III/IV 0
Noema Pharma AG Commercial 1 Phase II 0
Gw Research Limited Commercial 1 Phase III 0
Oils4cure S.L. Commercial 1 Phase III 1
Grin Therapeutics Inc. Commercial 1 Phase I/II 0
New trials by year
2023
2
2024
3
← All indication landscapes